BMS Plant Expansion to Push Biologics Development and Manufacturing
Bristol Myers-Squibb says its $250m (€191m) expansion of its US biologics facility will centralize its processes and become a springboard to launch new products.
Bristol Myers-Squibb says its $250m (€191m) expansion of its US biologics facility will centralize its processes and become a springboard to launch new products.
Update
Thermo Fisher Scientific has agreed to purchase genetic testing equipment maker Life Technologies for $13.6B in one of the biggest acquisitions of the year.